Septerna (SEPN) Projected to Post Quarterly Earnings on Monday

Septerna (NASDAQ:SEPN) is projected to issue its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Septerna to post earnings of ($0.4150) per share and revenue of $20.78 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The firm had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. On average, analysts expect Septerna to post ($1.41) EPS for the current fiscal year and ($2.21) EPS for the next fiscal year.

Septerna Stock Performance

Shares of SEPN opened at $44.00 on Monday. The firm’s 50-day moving average is $38.95 and its two-hundred day moving average is $32.10. Septerna has a twelve month low of $17.55 and a twelve month high of $51.10. The firm has a market capitalization of $2.05 billion, a P/E ratio of -81.48 and a beta of 2.20.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SEPN. HC Wainwright lifted their price target on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. upped their price target on Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, August 19th. Guggenheim raised their price objective on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. JonesTrading lifted their price objective on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Finally, Stifel Nicolaus set a $49.00 target price on Septerna in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.44.

Insider Transactions at Septerna

In other news, COO Elizabeth Bhatt sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $7,665,196. This trade represents a 12.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Daniel D. Long sold 3,333 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 32,333 shares of company stock valued at $1,375,727. 5.80% of the stock is currently owned by company insiders.

About Septerna

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.